2 results
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…
Approved WMOCompleted
1. To investigate the tolerability and safety of HALF-MIS used in elderly patients with chronic musculoskeletal pain.2. To investigate the effect on pain of HALF-MIS used in elderly patients with chronic musculoskeletal pain.3. To investigate the…